Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Extension Study of Ataluren in Nonsense Mutation-Mediated Duchenne and Becker Muscular Dystrophy
2008-007648-32Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ataluren in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Long-term safety of ataluren. Started Feb 2009; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on 2008-007648-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007648-32.